Bayer stock forecast: Guidance reaffirmed, litigation in focus

Bayer is a German life sciences company whose 2026 outlook centres on reaffirmed guidance, ongoing Roundup litigation, and the potential effect of US pharmaceutical tariffs. Past performance is not a reliable indicator of future results. Explore third-party BAYN price targets and technical analysis.

By Dan Mitchell11 minutes ago

Photo: Shutterstock

Bayer AG (BAYN) is trading at €40 as of 12:08pm UTC on 9 April 2026, within an intraday range of €39.75–€40.85 on Capital.com's quote feed. Past performance is not a reliable indicator of future results.

Support for the stock has followed Bayer's management reaffirming its 2026 financial guidance, targeting adjusted EBITDA of €9.6–€10.1bn and currency-adjusted net sales of €45–€47bn, despite headwinds from US pharmaceutical tariffs, which the company said it expects to partly offset through existing EU–US trade agreements (AD HOC NEWS, 9 April 2026). Ongoing Roundup litigation remains an overhang, with Monsanto having filed its opening brief at the US Supreme Court in the Durnell case on 23 February 2026, a ruling on federal pre-emption that could materially alter the litigation outlook (Bayer.com, 3 March 2026). Separately, Goldman Sachs reduced its stake in BAYN while maintaining a Buy rating with a price target of €54.50 (AD HOC NEWS, 8 April 2026).

Bayer stock forecast 2026–2030: Third-party price targets

As of 9 April 2026, third-party Bayer stock predictions reflect a predominantly constructive view on BAYN, with targets dispersed across a wide range as analysts weigh glyphosate litigation progress, execution against 2026 earnings guidance, and US tariff exposure.

Barclays (broker note – Buy)

Barclays analyst Charles Pitman-King maintains a Buy rating on Bayer, reiterating the house BAYN stock forecast of €48. The note maintains a constructive stance after management reconfirmed full-year guidance, with Pitman-King citing 2026 as a likely trough year for pharmaceuticals before a projected return to mid-single-digit sales growth from 2027 (The Globe and Mail, 31 March 2026).

UBS (broker note – Buy, maintained)

UBS analyst Geoff Haire reaffirms a Buy rating on BAYN, retaining a price target of €52. Haire's rationale centres on what the bank describes as a range of opportunities across the pharmaceuticals pipeline and crop science division, with litigation de-risking through the glyphosate settlement framework cited as a supporting condition (MarketScreener, 26 March 2026).

MarketBeat (broker consensus – Moderate Buy)

MarketBeat's compiled consensus across nine analysts covering BAYRY returns an aggregate rating of Moderate Buy, reflecting a split of two sell ratings, five buys, and two strong buys. The dispersion in individual views, spanning from Strong Sell to Strong Buy, highlights the binary nature of the glyphosate and tariff outcomes that remain outstanding for the stock (MarketBeat, 7 April 2026).

MarketScreener (analyst consensus – Outperform)

MarketScreener's consensus across 19 analysts places the average 12-month price target at €46.53, with a high estimate of €60 and a low estimate of €23 against a last close of €40.48. The mean consensus rating stands at Outperform, with the average target implying a spread of approximately +14.9% from the 8 April 2026 close (MarketScreener, 8 April 2026).

Across these sources, Bayer stock predictions range from €23 (Deutsche Bank, Neutral) to €60 at the top of the distribution. Buy-rated houses including Barclays and UBS cluster around €48–€52, while the common thread across constructive notes is progress on litigation resolution and the view that 2026 could mark an earnings trough.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

BAYN stock price: Technical overview

The BAYN stock price trades at €40 as of 12:08pm UTC on 9 April 2026, sitting above the 20-, 30-, 100- and 200-day simple moving averages (SMAs) at roughly €39, €39, €39 and €33 respectively, according to TradingView data. The price sits below the 50-day SMA at €41.66, which currently registers a sell signal and marks the nearest overhead moving average reference on the daily chart.

The 14-day relative strength index (RSI) reads 50.96, placing it in neutral territory, with momentum alone implying no strong directional bias. The average directional index (ADX) at 14 registers below 15, indicating a weak or non-trending environment by TradingView's measure.

On the topside, the classic R1 pivot at €42.12 is the nearest overhead reference; a daily close above that level would place the R2 area near €44.85 in view. The Hull moving average (nine-period) at €40.18 sits fractionally above the last price and also registers a sell signal, adding to the cluster of short-term resistance in the €40–€42 range.

On the downside, the classic pivot point at €38.66 represents initial support, with the 100-day SMA near €38.79 forming a nearby moving average shelf. A move through that zone would bring the S1 classic pivot at €35.93 into view as the next reference, according to TradingView pivot data (TradingView, 9 April 2026).

This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

Bayer share price history (2024–2026)

BAYN’s stock price closed at around €27.60 on 10 April 2024, near levels that persisted through much of mid-2024 as the stock moved sideways in a tight €25–€30 band through the summer and into early autumn, weighed down by ongoing Roundup litigation uncertainty and a subdued earnings backdrop.

The picture shifted more dramatically in late 2024 and into 2025. BAYN closed 2024 at around €19.40 - a sharp decline from the mid-year range - before touching a multi-year low of approximately €18.45 intraday on 7 April 2025. From that floor, the stock staged a sustained recovery across the second half of 2025, climbing from roughly €26.10 in early November 2025 to close the year at €37.05 on 30 December 2025, representing a full-year 2025 gain of approximately 90.5% from the January 2025 open of €19.45.

The rally extended into early 2026, with BAYN reaching a two-year high of €49.50 on 17 February 2026, before retreating sharply to a March low of €35.30 on 4 March 2026 - a pullback of approximately 28.4% from that peak - amid a 2026 profit guidance miss that disappointed market expectations. The stock has since partially recovered. BAYN closed at €40.05 on 9 April 2026, approximately 5.3% up year to date and roughly 104.3% up year on year from the April 2025 low.

Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.

Bayer (BAYN): Capital.com analyst view

BAYN's recovery from its April 2025 lows reflects a confluence of factors that appears to have shifted sentiment in a more constructive direction over the past year. Bayer's pharmaceuticals division reported a record 2025 with five product approvals and six positive Phase III readouts, and management confirmed at its April 2026 Pharma Media Day that the division is on track to return to mid-single-digit growth from 2027, with operating margin expansion towards 30% targeted by 2030 (Bayer.com, 1 April 2026). On the litigation front, a proposed $7.25bn Roundup class-action settlement framework, if court-approved, could reduce a key source of investor uncertainty. However, the pending US Supreme Court review of the Durnell pre-emption case means the legal picture is not yet resolved, and 2026 free cash flow is expected to remain negative – guided at –€2.5bn to –€1.5bn – due to settlement-related outflows (Bayer.com, 4 March 2026).

Bayer's US head confirmed in April 2026 that the company sees no need to revise its 2026 guidance in response to new US pharmaceutical tariffs, citing the EU–US trade framework – under which generic pharmaceuticals from the EU are subject to only the MFN tariff rate and branded drug tariffs are capped at 15% – as a mitigating factor (Reuters, 7 April 2026). That position may offer some support to sentiment among investors monitoring the tariff situation (

Seeking Alpha, 7 April 2026). However, the tariff landscape remains fluid, and if trade conditions deteriorate beyond current assumptions, or if the Roundup settlement faces legal obstacles, balance-sheet pressure from Bayer's net financial debt – guided to rise to approximately €32.0–€33.0bn by end-2026 – could weigh more heavily on the stock than current guidance implies (Bayer.com, 4 March 2026).

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Capital.com’s client sentiment for Bayer CFDs

As of 9 April 2026, Capital.com client positioning in Bayer CFDs stands at 97.4% buyers vs 2.6% sellers, which places it firmly in heavy-buy territory with buyers ahead by 94.8 percentage points. This makes it one of the most one-sided long skews across the platform. This snapshot reflects open positions on Capital.com at the time of writing and can change rapidly as market conditions evolve.

Summary – Bayer 2026

As of 12:08pm UTC on 9 April 2026, BAYN trades at €40, up approximately 5.3% year to date and roughly 104% above its April 2025 low of €19.40.
TradingView indicators show a broadly neutral momentum picture, with the 14-day RSI at 50.96 and ADX at 14.85, suggesting a weak trending environment. Most short-term moving averages signal buy, while the 50-day SMA at €41.66 stands as near-term overhead resistance.
Key drivers include Bayer's reaffirmed 2026 EBITDA guidance of €9.6–€10.1bn, a record pharmaceuticals pipeline, and the proposed $7.25bn Roundup class-action settlement framework, which could reduce litigation uncertainty.
Risks include negative 2026 free cash flow from glyphosate settlement outflows, approximately €30bn in net debt, and an unresolved US Supreme Court Durnell pre-emption ruling that could materially alter the litigation trajectory.
Bayer's US head confirmed in April 2026 that US pharmaceutical tariffs are not expected to affect full-year guidance, citing the EU–US trade framework as a mitigating factor.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most Bayer stock?

Bayer’s shareholder base is widely distributed across institutional and retail investors, and the largest holdings can change over time as funds adjust their positions. In the context of this article, one notable recent development was Goldman Sachs reducing its stake while maintaining a Buy rating. For readers assessing ownership, it can be more useful to focus on how changes in major holdings may affect market sentiment rather than treating any single shareholder as a fixed long-term signal.

What is the 5 year Bayer share price forecast?

There is no single reliable five-year BAYN stock forecast, because long-term outcomes depend on several variables that remain uncertain. These include progress in Roundup litigation, execution against Bayer’s pharmaceuticals and crop science strategy, debt reduction, and the effect of tariffs or broader trade policy. Analyst targets in the article focus on a 12-month view, not a five-year horizon, so any longer-term projection should be treated as highly uncertain rather than a firm expectation.

Is Bayer a good stock to buy?

Whether Bayer is a good stock to buy depends on an investor’s objectives, time horizon, and tolerance for risk. The article outlines both supportive factors and downside risks. Supportive factors include reaffirmed 2026 guidance, recovery from 2025 lows, and a stronger pharmaceuticals outlook. Risks include litigation uncertainty, negative free cash flow, and a sizeable debt load. That balance means the stock may appeal to some market participants, but it also carries material uncertainty.

Could Bayer stock go up or down?

Yes, Bayer stock could move in either direction, depending on how company-specific and external factors develop. Upward moves could be supported by progress on litigation, delivery against financial guidance, or stronger sentiment towards its pharmaceuticals pipeline. Downward pressure could come from legal setbacks, weaker cash flow, tariff developments, or broader market volatility. The technical picture in the article also points to a fairly neutral backdrop, which suggests price direction is not clearly established at present.

Should I invest in Bayer stock?

Whether you should invest in Bayer stock is a personal decision and not something this article can recommend. The article is designed to present market data, third-party forecasts, technical levels, and key risks in an objective way. If you are considering exposure, it may help to weigh Bayer’s recovery narrative against litigation risk, debt levels, and earnings uncertainty. You may also want to consider whether the stock fits your strategy, risk tolerance, and preferred time horizon.

Can I trade Bayer CFDs on Capital.com?

Yes, you can trade Bayer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.